Status:
TERMINATED
Lipids Profile in Primary Hyperparathyroidism
Lead Sponsor:
HaEmek Medical Center, Israel
Collaborating Sponsors:
University of Palermo
University of Zurich
Conditions:
Primary Hyperparathyroidism
Eligibility:
All Genders
18-85 years
Brief Summary
Severe Primary hyperparathyroidism (PHP) has been associated with increased cardiovascular morbidity and mortality. Hypertension, dyslipidemia and impaired glucose tolerance were demonstrated in sever...
Detailed Description
Severe traditional PHP has been associated with increased cardiovascular morbidity and mortality with an increase in acute MI prior to surgery.PHP is associated with increased prevalence of left ventr...
Eligibility Criteria
Inclusion
- Patients with primary hyperparathyroidism
Exclusion
- pregnant women
- patient taking hypolipidemic drugs
- patients with known cardiovascular, peripheral or cerebral atherosclerotic disease.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00961701
Start Date
October 1 2009
End Date
October 1 2016
Last Update
September 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Endocrine Institute , Haemek Medical Center
Afula, Israel, 18101